Published in Am J Psychiatry on January 01, 2006
Sevoflurane for Treatment-Resistant Depression | NCT05008939
Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KRF-EOL) | NCT05214417
Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev (2010) 11.25
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (2010) 10.97
The molecular neurobiology of depression. Nature (2008) 6.51
Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med (2007) 4.49
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry (2011) 3.62
NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature (2016) 3.18
Synaptic dysfunction in depression: potential therapeutic targets. Science (2012) 3.15
Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology (2010) 2.97
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology (2011) 2.79
A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry (2010) 2.77
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry (2012) 2.69
Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. Am J Psychiatry (2011) 2.58
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet (2006) 2.55
Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry (2010) 2.54
Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiatry (2009) 2.49
Depression and cardiovascular disease: healing the broken-hearted. JAMA (2006) 2.44
A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry (2009) 2.15
Prognostic subgroups for citalopram response in the STAR*D trial. J Clin Psychiatry (2014) 2.10
Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry (2010) 2.06
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Considerations on safety concerns about citalopram prescribing. Mayo Clin Proc (2012) 1.97
Long term effect of depression care management on mortality in older adults: follow-up of cluster randomized clinical trial in primary care. BMJ (2013) 1.91
Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther (2009) 1.90
A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. Biol Psychiatry (2013) 1.90
Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci (2012) 1.90
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry (2008) 1.86
Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology (2011) 1.85
Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther (2010) 1.74
Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat Med (2013) 1.70
A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry (2014) 1.69
Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J Consult Clin Psychol (2009) 1.67
When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology (2009) 1.65
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry (2006) 1.64
Structural Plasticity of the Hippocampus and Amygdala Induced by Electroconvulsive Therapy in Major Depression. Biol Psychiatry (2015) 1.63
Stuck in a rut: rethinking depression and its treatment. Trends Neurosci (2010) 1.60
Depression and diabetes: factors associated with major depression at five-year follow-up. Psychosomatics (2009) 1.53
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry (2006) 1.51
Default mode network mechanisms of transcranial magnetic stimulation in depression. Biol Psychiatry (2014) 1.51
A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am J Psychiatry (2012) 1.51
Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population. J Clin Psychiatry (2015) 1.51
Treatment of depression: antidepressant monotherapy and combination therapy. Psychiatry (Edgmont) (2007) 1.50
Growth modeling with nonignorable dropout: alternative analyses of the STAR*D antidepressant trial. Psychol Methods (2011) 1.49
The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. Eur Arch Psychiatry Clin Neurosci (2012) 1.49
Empirically derived decision trees for the treatment of late-life depression. Am J Psychiatry (2008) 1.48
International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials (2011) 1.46
Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med (2011) 1.45
Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. Eur Neuropsychopharmacol (2015) 1.45
Internet-delivered psychological treatments for mood and anxiety disorders: a systematic review of their efficacy, safety, and cost-effectiveness. PLoS One (2014) 1.44
Validity of the bereavement exclusion criterion for the diagnosis of major depressive episode. World Psychiatry (2007) 1.44
Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry (2013) 1.44
Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. J Am Acad Child Adolesc Psychiatry (2009) 1.44
Cognitive mechanisms of treatment in depression. Neuropsychopharmacology (2011) 1.43
Translating glutamate: from pathophysiology to treatment. Sci Transl Med (2011) 1.42
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
Yoga on our minds: a systematic review of yoga for neuropsychiatric disorders. Front Psychiatry (2013) 1.40
Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs (2012) 1.38
Brain rhythms and neural syntax: implications for efficient coding of cognitive content and neuropsychiatric disease. Dialogues Clin Neurosci (2012) 1.37
Addressing the challenges of a cross-national investigation: lessons from the Pittsburgh-Pisa study of treatment-relevant phenotypes of unipolar depression. Clin Trials (2008) 1.36
How to read a research paper: Reading between and beyond the lines. Indian J Psychiatry (2011) 1.35
A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol (2011) 1.32
SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet (2009) 1.32
Animal models of depression: molecular perspectives. Curr Top Behav Neurosci (2011) 1.31
Opioid receptors: distinct roles in mood disorders. Trends Neurosci (2012) 1.31
Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature. Psychopharmacology (Berl) (2010) 1.31
Neuromodulation for treatment-refractory major depressive disorder. CMAJ (2013) 1.29
Beyond efficacy: the STAR*D trial. Am J Psychiatry (2006) 1.28
Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med (2008) 1.28
Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets (2013) 1.26
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med (2016) 1.26
Strategies to improve the management of depression in primary care. Prim Care (2012) 1.26
Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). Neuropsychopharmacology (2010) 1.25
Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav (2011) 1.24
Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology (2012) 1.24
A critical review of human endotoxin administration as an experimental paradigm of depression. Neurosci Biobehav Rev (2009) 1.24
Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One (2008) 1.21
A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol (2012) 1.20
Enduring deficits in brain reward function after chronic social defeat in rats: susceptibility, resilience, and antidepressant response. Biol Psychiatry (2014) 1.19
Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend (2007) 1.19
Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med (2012) 1.19
Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis. Ann Fam Med (2007) 1.19
Culturally sensitive collaborative treatment for depressed chinese americans in primary care. Am J Public Health (2010) 1.18
Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry (2012) 1.17
Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs (2012) 1.17
Psychomotor retardation in depression: biological underpinnings, measurement, and treatment. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.17
Is there anything really novel on the antidepressant horizon? Curr Psychiatry Rep (2012) 1.17
Prevalence of incompletely penetrant Huntington's disease alleles among individuals with major depressive disorder. Am J Psychiatry (2010) 1.16
Remodeling of hippocampal spine synapses in the rat learned helplessness model of depression. Biol Psychiatry (2008) 1.16
Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci (2014) 1.15
Biomarkers to predict antidepressant response. Curr Psychiatry Rep (2010) 1.14
Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol (2011) 1.14
Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expression. Front Behav Neurosci (2014) 1.12
Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. J Psychiatr Res (2011) 1.12
Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol Psychiatry (2013) 1.12
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology (2010) 1.11
Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms. J Clin Child Adolesc Psychol (2008) 1.11
Personality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy. Can J Psychiatry (2008) 1.10
Depression and coronary artery disease: the association, mechanisms, and therapeutic implications. Psychiatry (Edgmont) (2009) 1.10
Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. J Psychiatr Res (2009) 1.09
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA (2003) 34.83
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41
Risperidone in children with autism and serious behavioral problems. N Engl J Med (2002) 9.35
Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med (2007) 8.07
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Surgery versus nonsurgical treatment of lumbar spinal stenosis: a randomized trial. Ann Intern Med (2015) 6.66
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials (2004) 6.64
A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry (2012) 6.34
Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA (2006) 6.26
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med (2006) 6.00
Medication augmentation after the failure of SSRIs for depression. N Engl J Med (2006) 5.16
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am (2003) 5.05
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry (2008) 4.98
Comparison of hypothermia and normothermia after severe traumatic brain injury in children (Cool Kids): a phase 3, randomised controlled trial. Lancet Neurol (2013) 4.20
Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry (2009) 3.96
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry (2006) 3.90
Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology (2006) 3.80
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry (2012) 3.73
Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2006) 3.66
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol (2008) 3.65
Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2003) 3.60
The epidemiology of chronic pain in children and adolescents revisited: a systematic review. Pain (2011) 3.49
Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2004) 3.43
Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry (2008) 3.40
Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry (2007) 3.38
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry (2011) 3.34
Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry (2009) 3.32
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry (2009) 3.17
Estimating Individualized Treatment Rules Using Outcome Weighted Learning. J Am Stat Assoc (2012) 3.13
Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry (2005) 3.05
An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry (2005) 3.03
Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task. J Psychiatr Res (2008) 3.01
Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol (2007) 2.99
Predictors of parent training efficacy for child externalizing behavior problems--a meta-analytic review. J Child Psychol Psychiatry (2006) 2.97
Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry (2005) 2.94
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry (2006) 2.90
Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry (2007) 2.87
Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry (2006) 2.85
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry (2007) 2.84